Transfusion Medicine Reviews
Volume 20, Issue 3 , Pages 230-241 , July 2006

Effects of Cardiac Surgery on Hemostasis

References 

  1. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann. Thorac. Surg. 2003;75:S715–S720
  2. Murphy GJ, Ascione R, Angelini GD. Coronary artery bypass grafting on the beating heart: Surgical revascularization for the next decade?. Eur. Heart J. 2004;25:2077–2085
  3. Herbertson M. Recombinant activated factor VII in cardiac surgery. Blood Coagul. Fibrinolysis. 2004;15:S31–S32(suppl 1)
  4. Skubas NJ, Despotis GJ. Optimal management of bleeding complications after cardiac surgery. Semin. Cardiothorac. Vasc. Anesth. 2001;5:217–228
  5. Spiess BD. Maintenance of homeostasis in coagulation during cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth. 1999;13:2–5(suppl)
  6. Unsworth-White MJ, Herriot A, Valencia O, et al. Resternotomy for bleeding after cardiac operation: A marker for increased morbidity and mortality. Ann. Thorac. Surg. 1995;59:664–667
  7. Hall TS, Sines JC, Spotnitz AJ. Hemorrhage related reexploration following open heart surgery: The impact of pre-operative and post-operative coagulation testing. Cardiovasc. Surg. 2002;10:146–153
  8. Dacey LJ, Munoz JJ, Baribeau YR, et al. Reexploration for hemorrhage following coronary artery bypass grafting: Incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch. Surg. 1998;133:442–447
  9. Sellman M, Intonti MA, Ivert T. Reoperations for bleeding after coronary artery bypass procedures during 25 years. Eur. J. Cardiothorac. Surg. 1997;11:521–527
  10. Ottino G, De Paulis R, Pansini S, et al. Major sternal wound infection after open heart surgery: A multivariate analysis of risk factors in 2,579 consecutive operative procedures. Ann. Thorac. Surg. 1987;44:173–179
  11. Parr KG, Patel MA, Dekker R, et al. Multivariate predictors of blood product use in cardiac surgery. J. Cardiothorac. Vasc. Anesth. 2003;17:176–181
  12. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb. Res. 2004;114:447–453
  13. Shattil SJ, Newman PJ. Integrins: Dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004;104:1606–1615
  14. MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biological amplifier. Nature. 1964;202:498–499
  15. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science. 1964;145:1310–1312
  16. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb. Haemost. 2001;85:958–965
  17. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J. Exp. Med. 2005;202:271–281
  18. Dahlback B, Villoutreix BO. The anticoagulant protein C pathway. FEBS Lett. 2005;579:3310–3316
  19. Roemisch J, Gray E, Hoffmann JN, et al. Antithrombin: A new look at the actions of a serine protease inhibitor. Blood Coagul. Fibrinolysis. 2002;13:657–670
  20. Quinsey NS, Greedy AL, Bottomley SP, et al. Antithrombin: In control of coagulation. Int. J. Biochem. Cell Biol. 2004;36:386–389
  21. Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J. Biol. Chem. 1982;257:2162–2169
  22. Rapaport SI. The extrinsic pathway inhibitor: A regulator of tissue factor–dependent blood coagulation. Thromb. Haemost. 1991;66:6–15
  23. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br. J. Haematol. 2005;129:307–321
  24. Despotis GJ, Filos KS, Zoys TN, et al. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: A multivariate analysis in cardiac surgical patients. Anesth. Analg. 1996;82:13–21
  25. Ziats NP, Pankowsky DA, Tierney BP, et al. Adsorption of Hageman factor (factor XII) and other human plasma proteins to biomedical polymers. J. Lab. Clin. Med. 1990;116:687–696
  26. Boisclair MD, Lane DA, Philippou H, et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood. 1993;82:3350–3357
  27. Burman JF, Chung HI, Lane DA, et al. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet. 1994;344:1192–1193
  28. Kappelmayer J, Bernabei A, Edmunds LH, et al. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res. 1993;72:1075–1081
  29. Boyle EM, Verrier ED, Spiess BD. Endothelial cell injury in cardiovascular surgery: The procoagulant response. Ann. Thorac. Surg. 1996;62:1549–1557
  30. Chung JH, Gikakis N, Rao AK, et al. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation. 1996;93:2014–2018
  31. de Haan J, Boonstra PW, Monnink SH, et al. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. Ann. Thorac. Surg. 1995;59:901–907
  32. Aldea GS, Soltow LO, Chandler WL, et al. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J. Thorac. Cardiovasc. Surg. 2002;123:742–755
  33. Teufelsbauer H, Proidl S, Havel M, et al. Early activation of hemostasis during cardiopulmonary bypass: Evidence for thrombin mediated hyperfibrinolysis. Thromb. Haemost. 1992;68:250–252
  34. Holloway DS, Summaria L, Sandesara J, et al. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients. Thromb. Haemost. 1988;59:62–67
  35. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann. Thorac. Surg. 1998;66:2145–2152
  36. Harker LA, Malpass TW, Branson HE, et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha-granule release. Blood. 1980;56:824–834
  37. Greilich PE, Carr ME, Carr SL, et al. Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage. Anesth. Analg. 1995;80:459–465
  38. Boldt J, Knothe C, Welters I, et al. Normothermic versus hypothermic cardiopulmonary bypass: Do changes in coagulation differ?. Ann. Thorac. Surg. 1996;62:130–135
  39. Valeri CR, Feingold H, Cassidy G, et al. Hypothermia-induced reversible platelet dysfunction. Ann Surg. 1987;205:175–181
  40. Michelson AD, MacGregor H, Barnard MR, et al. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb. Haemost. 1994;71:633–640
  41. Rosenberg RD. Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am. J. Med. 1989;87:2S–9S
  42. Bull BS, Korpman RA, Huse WM, et al. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J. Thorac. Cardiovasc. Surg. 1975;69:674–684
  43. Hirsh J, Anand SS, Halperin JL, et al. American Heart Association. Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation. 2001;103:2994–3018
  44. Carr JA, Silverman N. The heparin-protamine interaction. A review. J. Cardiovasc. Surg. (Torino). 1999;40:659–666
  45. Mochizuki T, Olson PJ, Szlam F, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth. Analg. 1998;87:781–785
  46. Comunale ME, Van Cott EM. Heparin-induced thrombocytopenia. Int. Anesthesiol. Clin. 2004;42:27–43
  47. Chong BH, Chong JH. Heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther. 2004;2:547–559
  48. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: Recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:311S–337S(suppl 3)
  49. Dietrich W, Dilthey G, Spannagl M, et al. Warfarin pretreatment does not lead to increased bleeding tendency during cardiac surgery. J. Cardiothorac. Vasc. Anesth. 2005;9:250–254
  50. Suchman AL, Griner PF. Diagnostic uses of the activated partial thromboplastin time and prothrombin time. Ann. Intern. Med. 1988;104:810–816
  51. Rohrer MJ, Michelotti MC, Nahrwold DL. A prospective evaluation of the efficacy of preoperative coagulation testing. Ann. Surg. 1988;208:554–557
  52. Hattersley PG. Activated coagulation time of whole blood. JAMA. 1966;196:436–440
  53. Swartz MF, Fink GW, Searles B. Aprotinin and hemostasis monitoring concerns during cardiac surgery. J Extra-Corpor. Technol. 2004;36:375–383
  54. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994;108:1076–1082
  55. Hartert H. Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren. Klin. Wschr. 1948;26:577–583
  56. Spiess BD, Gillies BS, Chandler W, et al. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J. Cardiothorac. Vasc. Anesth. 1995;9:168–173
  57. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth. Analg. 1999;88:312–319
  58. Cammerer U, Dietrich W, Rampf T, et al. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth. Analg. 2003;96:51–57
  59. Franchini M. The platelet-function analyzer (PFA-100) for evaluating primary hemostasis. Hematology. 2005;10:177–181
  60. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br. J. Haematol. 2005;130:3–10
  61. Forestier F, Coiffic A, Mouton C, et al. Platelet function point-of-care tests in post-bypass cardiac surgery: Are they relevant?. Br. J. Anaesth. 2002;89:715–721
  62. Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann. Thorac. Surg. 1994;58:1580–1588
  63. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, et al. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: A meta-analysis. Circulation. 1999;99:81–89
  64. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Perioperative Transfusion (ISPOT) Investigators. Anesth. Analg. 1997;85:1258–1267
  65. Fergusson D, Glass KC, Hutton B, et al. Randomized controlled trials of aprotinin in cardiac surgery: Could clinical equipoise have stopped the bleeding?. Clin. Trials. 2005;2:218–229
  66. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints. Lancet. 1999;354:1940–1947
  67. Murkin JM. Attenuation of neurologic injury during cardiac surgery. Ann. Thorac. Surg. 2001;72:S1838–S1844
  68. Harmon DC, Ghori KG, Eustace NP, et al. Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: A pilot randomized controlled study. Can. J. Anaesth. 2004;51:1002–1009
  69. Mangano DT, Tudor JC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N. Engl. J. Med. 2006;354:353–365
  70. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion. 2006;(online first)
  71. Kincaid EH, Ashburn DA, Hoyle JR, et al. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery?. Ann. Thorac. Surg. 2005;80:1388–1393
  72. Beierlein W, Scheule AM, Dietrich W, et al. Forty years of clinical aprotinin use: A review of 124 hypersensitivity reactions. Ann. Thorac. Surg. 2005;79:741–748
  73. Wells PS. Safety and efficacy of methods for reducing perioperative allogeneic transfusion: A critical review of the literature. Am. J. Ther. 2002;9:377–388
  74. Mahdy AM, Webster NR. Perioperative systemic haemostatic agents. Br. J. Anaesth. 2004;93:842–858
  75. Cattaneo M, Harris AS, Stromberg U, et al. The effect of desmopressin on reducing blood loss in cardiac surgery—A meta-analysis of double-blind, placebo-controlled trials. Thromb. Haemost. 1995;74:1064–1070
  76. Dilthey G, Dietrich W, Spannagl M, et al. Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J. Cardiothorac. Vasc. Anesth. 1993;7:425–430
  77. Sheridan DP, Card RT, Pinilla JC, et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid–induced platelet dysfunction. Can. J. Surg. 1994;37:33–36
  78. Stanworth SJ, Brunskill SJ, Hyde CJ, et al. Is fresh frozen plasma clinically effective? a systematic review of randomized controlled trials. Br. J. Haematol. 2004;126:139–152
  79. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br. J. Haematol. 2004;126:11–28
  80. Casbard AC, Williamson LM, Murphy MF, et al. The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A systematic review. Anaesthesia. 2004;59:550–558
  81. Ciavarella D, Reed RL, Counts RB, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br. J. Haematol. 1987;67:365–368
  82. Stainsby D, MacLennan S, Hamilton PJ. Management of massive blood loss: A template guideline. Br. J. Anaesth. 2000;85:487–491
  83. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth. Analg. 1995;81:360–365
  84. Norfolk DR, Ancliffe PJ, Contreras M, et al. Consensus Conference on Platelet Transfusion, Royal College of Physicians of Edinburgh, 27-28 November 1997. Synopsis of background papers. Br. J. Haematol. 1998;101:609–617
  85. British Committee for Standards in Haematology, Blood Transfusion Taskforce: Guidelines for the use of platelet transfusions. Br. J. Haematol. 2003;122:10–23
  86. Simon TL, Akl BF, Murphy W. Controlled trial of routine administration of platelet concentrates in cardiopulmonary bypass surgery. Ann. Thorac. Surg. 1984;37:359–364
  87. Valles J, Santos MT, Aznar J, et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood. 1991;78:154–162
  88. Peyrou V, Lormeau JC, Herault JP, et al. Contribution of erythrocytes to thrombin generation in whole blood. Thromb. Haemost. 1999;81:400–406
  89. Uijttewaal WS, Nijhof EJ, Bronkhorst PJ, et al. Near-wall excess of platelets induced by lateral migration of erythrocytes in flowing blood. Am. J. Physiol. 1993;264:H1239–H1244
  90. Blajchman MA, Bordin JO, Bardossy L, et al. The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. Br. J. Haematol. 1994;86:347–350
  91. Small M, Lowe GD, Cameron E, et al. Contribution of the haematocrit to the bleeding time. Haemostasis. 1983;13:379–384
  92. Escolar G, Garrido M, Mazzara R, et al. Experimental basis for the use of red cell transfusion in the management of anemic-thrombocytopenic patients. Transfusion. 1988;28:406–411
  93. Livio M, Benigni A, Remuzzi G. Coagulation abnormalities in uremia. Semin. Nephrol. 1985;5:82–90
  94. Hardy JF, De Moerloose P, Samama M. Massive transfusion and coagulopathy: Pathophysiology and implications for clinical management. Can. J. Anaesth. 2004;51:293–310
  95. Goodnough LT, Lublin DM, Zhang L, et al. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion. 2004;44:1325–1331
  96. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Crit. Care Med. 2005;33:883–890
  97. He S, Blomback M, Jacobsson Ekman G, et al. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J. Thromb. Haemost. 2003;1:1215–1219
  98. Lisman T, Moschatsis S, Adelmeijer J, et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor–independent thrombin generation. Blood. 2003;101:1864–1870
  99. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood. 2002;99:175–179
  100. Dietrich W, Spannagl M. Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anesth. Analg. 2002;94:1369–1370
  101. Raivio P, Suojaranta-Ylinen R, Kuitunen AH. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann. Thorac. Surg. 2005;80:66–71
  102. von Heymann C, Schoenfeld H, Sander M, et al. Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: A rationale for the use of coagulation factor concentrates?. Heart Surg. Forum. 2005;8:E39–E41
  103. Yilmaz BT, Alioglu B, Ozyurek E, et al. Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr. Cardiol. 2005;26:843–845
  104. Tokunaga C, Hiramatsu Y, Horigome H, et al. Palliative open heart surgery in an infant with factor VII deficiency. Ann. Thorac. Surg. 2003;76:2093–2094
  105. Aggarwal A, Malkovska V, Catlett JP, et al. Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage. Thromb. J. 2004;2:9
  106. Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: A propensity score-matched case-control analysis. Transfusion. 2005;45:26–34
  107. Tobias JD, Simsic JM, Weinstein S, et al. Recombinant factor VIIa to control excessive bleeding following surgery for congenital heart disease in pediatric patients. J. Intensive Care Med. 2004;19:270–273
  108. Pychynska-Pokorska M, Moll JJ, Krajewski W, et al. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr. Crit. Care Med. 2004;5:246–250
  109. Egan JR, Lammi A, Schell DN, et al. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med. 2004;30:682–685

PII: S0887-7963(06)00015-0

doi: 10.1016/j.tmrv.2006.03.003

Transfusion Medicine Reviews
Volume 20, Issue 3 , Pages 230-241 , July 2006

Article Tools

* Image Usage & Resolution